Physician profile
Theodore Prentice
NPI 1194733436
$9,005.78
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,486 · 2020: $1,780 · 2021: $2,563 · 2022: $1,120 · 2023: $56.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $965.82 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $920.91 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $792.45 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $678.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $550.33 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $469.95 | 2019-2022 | |
| Biogen, INC. | $455.97 | 2019-2022 | |
| Sk Life Science, INC. | $401.01 | 2020-2022 | |
| Abbvie INC. | $378.90 | 2021-2022 | |
| Livanova USA, INC. | $358.56 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $331.85 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $295.04 | 2019-2021 | |
| Allergan, INC. | $275.82 | 2020 | |
| Kyowa Kirin, INC. | $255.82 | 2019-2021 | |
| Emd Serono, INC. | $231.31 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $212.85 | 2019-2021 | |
| Acorda Therapeutics, INC | $205.48 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $166.10 | 2019-2022 | |
| Eisai INC. | $122.18 | 2019 | |
| Abbott Laboratories | $120.15 | 2020-2023 | Infinity |
| Avanir Pharmaceuticals, INC. | $97.04 | 2019-2020 | |
| Genentech USA, INC. | $90.35 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $77.80 | 2019-2022 | |
| Amgen INC. | $77.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.00 | 2021 | |
| Boston Scientific Corporation | $63.88 | 2019-2023 | |
| Neurelis, INC. | $47.36 | 2021-2022 | |
| Genzyme Corporation | $44.97 | 2019-2020 | |
| Lilly USA, LLC | $43.15 | 2019-2022 | |
| Mdd US Operations, LLC | $40.89 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.88 | 2021 | |
| Banner Life Sciences, LLC | $24.12 | 2022 | |
| Greenwich Biosciences, INC. | $24.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.24 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.02 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.10 | 2019 | |
| Medtronic Vascular, INC. | $16.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Prentice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.